Oxford spinout OMass Technologies provides native mass spectrometry to pharma and biotech | University of Oxford
Dame Carol Robinson
Professor Dame Carol Robinson, one of the pioneers of structural mass spectrometry and a founder of OMass.

Image credit: Isis Innovation

Oxford spinout OMass Technologies provides native mass spectrometry to pharma and biotech

OMass Technologies, a spinout from the University of Oxford's Department of Chemistry, is the first company to conquer the challenge of deciphering the interactions of membrane proteins by using native mass spectrometry. 

It offers a new way to understand exactly how these important molecules respond to therapeutics, and in the process speeds up the development of new drugs.

The company has raised £1 million from Oxford Sciences Innovation to launch the enabling technology platform and has established partnerships with international pharmaceutical and biotech companies to guide their drug discovery programs.

OMass Technologies allows scientists to understand binding mechanisms of 'classic' small molecule therapeutic drugs, which are still the major focus for most pharmaceutical projects. At the same time it will provide insights into how to design better biologics. It will also offer scientists the ability to interrogate more complex drug targets, including membrane proteins, without the need to 'denature' or destroy their 3D structure.

Professor Dame Carol Robinson, one of the pioneers of structural mass spectrometry and a founder of OMass, said: 'Over 50% of approved drug targets are membrane proteins. These proteins are notoriously challenging for structural studies. But the new mass spectrometry methods we are developing here at Oxford allow us to understand the structure of membrane proteins and how they are affected by small molecule binding in much more detail.

'This means we will be able to offer a new view for drug candidates. We'll also be able to offer incredibly useful insights into how drugs interact within cells – for instance how they interact with the lipid membrane and how individual lipids influence drug binding, all prior to any pre-clinical or clinical trials.'

OMass CEO Dr Jonathan Hopper said: 'OMass will offer pharmaceutical and biotech companies the opportunity to access world-leading structural mass spectrometry technology, without having to set up sophisticated instrumentation and acquire expertise in-house. This provides new ways to study complex protein assemblies and their interactions with other biological molecules.'

The team has developed mass spectrometry methodologies based on 25 years of research and intellectual property from Oxford, and already has partnerships with many life science companies. Oxford's Isis Innovation supported them by filing patent applications covering the methodology, which describes applications of mass spectrometry to drug screening of membrane proteins.

OMass will establish an independent state-of-the-art laboratory in Oxford, which will operate in synergy with the research groups at the University of Oxford.

Dr Adam Stoten, Head of Technology Transfer (Life Sciences) at Isis Innovation, said: 'For scientists, pharmaceutical companies and their investors, OMass offers the chance to understand how new therapeutic drugs act "in the wild" by characterising intact membrane protein assemblies.'